Henry Mok, MD PhD
Department of GU Radiation Oncology, Division of Radiation Oncology
Present Title & Affiliation
Primary Appointment
Professor, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2005 | Baylor College of Medicine, Houston, Texas, US, MD |
| 2004 | Baylor College of Medicine, Houston, Texas, US, Ph.D. in Molecular and Human Genetics |
| 1996 | Rice University, Houston, Texas, US, BA in Chemistry and Biochemistry |
Postgraduate Training
| 2007-2011 | Residency, University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2006-2007 | Transitional Internship, The Methodist Hospital, Houston, Texas |
| 2006-2006 | Research Fellowship, University of Texas MD Anderson Cancer Center, Houston, Texas |
Licenses & Certifications
| 2012 | American Board of Radiology Board Certificate Radiation Oncology |
| 2011 | Texas Medical Board License |
Experience & Service
Faculty Academic Appointments
Associate Professor, Radiation Oncology, Baylor College of Medicine, Houston, TX, 2019 - 2020
Assistant Professor, Radiation Oncology, Baylor College of Medicine, Houston, TX, 2012 - 2019
Assistant Professor, Texas Oncology, Houston, TX, 2011 - 2012
Administrative Appointments/Responsibilities
Department Patient Safety and Quality Officer (PSQO), Genitourinary (GU) Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, 2023 - Present
Residency Program Director, Radiation Oncology, Baylor College of Medicine, Houston, Texas, 2017 - 2020
Chair, Quality Assurance Committee, Radiation Oncology, Baylor College of Medicine, 2013 - 2020
Intramural Institutional Committee Activities
Representative for the Division of Radiation Oncology, Parmacy and Therapeutics, The University of Texas MD Anderson Cancer Center, 2024 - Present
Representative for Genitourinary Radiation Oncology, New Faculty Hiring Interview Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Committee Member representing Genitourinary Radiation Oncology, Department of Urology Chair Search Committee, The University of Texas MD Anderson Cancer Center, 2024 - 2024
Representative for Genitourinary Radiation Oncology (Alternate), Credentials Committee of the Medical Staff (CCMS), University of Texas MD Anderson Cancer Center, 2024 - Present
Reviewer, Prostate Cancer RFA Review Committee, The University of Texas MD Anderson Cancer Center, 2023
Representative for Genitourinary Radiation Oncology, New Faculty Hiring Interview Committee, The University of Texas MD Anderson Cancer Center, 2023
Representative for Genitourinary Radiation Oncology, New Faculty Hiring Interview Committee, The University of Texas MD Anderson Cancer Center, 2022
Representative for Genitourinary Radiation Oncology, Radiation Oncology Finance Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present
Senator representative for the Department of Radiation Oncology, Faculty Senate, Baylor College of Medicine, 2015 - 2019
Extramural Institutional Committee Activities
GU disease site liaison, Rush/MD Anderson Peer Review, Rush University Medical Center, 2024 - Present
Voting Member representing Department of Radiation Oncology, Harris Health System Cancer Committee, Baylor College of Medicine, 2016 - 2020
Honors & Awards
| 2024 - Present | Top 10% Provider, MD Anderson Cancer Center |
| 2023 - Present | Top 10% Provider, MD Anderson Cancer Center |
| 2022 - 2023 | Top 10% Provider, MD Anderson Cancer Center |
| 2021 | Top 10% Provider, MD Anderson Cancer Center |
| 2019 | Faculty Leadership Program, Baylor College of Medicine |
| 2014 - 2015 | Association of Residents in Radiation Oncology Educator of the Year Award, Baylor College of Medicine |
| 2004 | Best Poster Presentation, BCM MD/PhD Symposium |
| 1996 | Magna cum Laude, Phi Beta Kappa Honor Society |
| 1996 | James B. Walker Outstanding Senior in Biochemistry, Rice University |
| 1996 | Presidential Scholar, Baylor College of Medicine |
| 1992 - 2005 | Rice/Baylor Medical Scholars Program, Rice University/Baylor College of Medicine |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2024. Adjuvant/Salvage Radiation for Prostate Cancer. Planning clinic conference. Houston, Texas, US.
- 2023. Adjuvant/Salvage Radiation for Prostate Cancer. Planning clinic conference. Houston, Texas, US.
- 2022. Adjuvant/Salvage Radiation for Prostate Cancer. Planning clinic conference. Houston, Texas, US.
- 2022. Review of GU Radiation Oncology. Mock oral lecture series. Houston, Texas, US.
- 2021. Adjuvant/Salvage Radiation for Prostate Cancer. Planning clinic conference. Houston, Texas, US.
- 2021. Chronic gastrointestinal (GI) toxicity after proton radiotherapy for prostate cancer. Proton Physics Planning and Outcomes (PPPO). Houston, Texas, US.
- 2021. Prostate Brachytherapy. Invited. Didactic conference for Baylor College of Medicine Radiation Oncology Residency Program. Houston, Texas, US.
- 2021. Introduction to radiation oncology. "Meet the Professor" presentation to summer research students. Houston, Texas, US.
- 2021. Rectal bleeding after prostate radiotherapy. Division of Radiation Oncology Quality Assurance Conference. Houston, Texas, US.
- 2017. Radiation Therapy in Rectal Cancer. Conference. Radiation Therapy in Rectal Cancer, US.
- 2017. Radiotherapy Advances for Mesothelioma. Conference. Radiotherapy Advances for Mesothelioma, US.
- 2004. A ferroportin mutation in mouse confers novel insight into the regulation of iron homeostasis and erythropoiesis. Conference. A ferroportin mutation in mouse confers novel insight into the regulation of iron homeostasis and erythropoiesis. Houston, TX, US.
Regional Presentations
- 2023. Proton therapy for genitourinary malignancies. MD Anderson Particle Therapy Institute - GU Proton Therapy Webinar, US.
- 2021. Proton for pelvic malignancies – Interactive QA for presentations on prostate cancer and abdominopelvic sarcoma. Pelvic Proton Therapy Training Webinar, US.
National Presentations
- 2023. MRI-Assisted Radiosurgery (MARS) for the management of localized and recurrent prostate cancer. Invited. American Association of Physicists in Medicine 65th Annual Meeting and Exhibition. Houston, TX, US.
- 2014. Metastatic spinal cord compression: The role of radiation oncology today. Invited. Santa Monica, CA, US.
International Presentations
- 2023. Current Status of Proton Therapy for Prostate Cancer. Invited. 2023 Guangdong-Hong Kong-Macau Greater Bay Area International Oncology Conference and the 3rd Annual Academic Meeting of MD Anderson Cancer Center and Concord Medical (Virtual), US.
Grant & Contract Support
| Date: | 2002 - 2004 |
| Title: | National Research Service Award from the National Institute of Environmental Health Sciences (NIEHS) |
| Funding Source: | NIH |
| Role: | Fellow |
Selected Publications
Peer-Reviewed Articles
- El Kouzi, Z, Mohammed, MA, Rooney, M, Kouzy, R, Chen, JJ, Shah, SJ, Al Bitar, T, Gadoue, S, Hassanzadeh, CJ, Frank, SJ, Tran, P, Tang, C, Choi, S, Park, RJ, Hoffman, K, McGuire, SE, Mok, H, Nguyen, Q, Samman, AB, Rahman, Z, Shelan, M, Eid, T, Mohamad, O. Association between author specialty and reported outcomes in non-randomized comparisons of prostatectomy versus radiation. JNCI Cancer Spectrum 10(4), 2026. e-Pub 2026. PMID: 42390011.
- Marqueen, KE, Corrigan, KL, Prajapati, S, Kudchadker, RJ, Manzar, G, Cha, E, Mok, H, Tang, C, Hassanzadeh, CJ, Mohamad, O, Frank, SJ. Assessment of brachytherapy-induced prostate edema on postimplant dosimetric analysis in patients treated with magnetic resonance imaging–assisted radiosurgery (MARS). Brachytherapy 25(1):24-30, 2026. e-Pub 2026. PMID: 41271489.
- Sherry, AD, Siddiqui, BA, Haymaker, CL, Fellman, B, Medina-Rosales, M, Bathala, TK, Wang, S, Liu, S, Seo, A, Kobayashi, K, Lu, H, Troncoso, P, Chun, SG, Ha, CS, Mayo, LL, Mok, H, Park, RJ, Chapin, BF, Phillips, RM, Deek, MP, Kovitz, CA, Aparicio, A, Zurita-Saavedra, A, Pilie, PG, Cohen, L, Choi, S, Reuben, A, Tran, PT, Corn, P, Subudhi, SK, Tang, C. Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer. European urology 88(5):496-509, 2025. e-Pub 2025. PMID: 40750497.
- Hassanzadeh, CJ, Kuban, DA, Pasyar, S, Bassett Jr, R, Troncoso, P, Ansari, M, Schlembach, PJ, McGuire, SE, Nguyen, Q, Frank, SJ, Mok, H, Mohamad, O, Park, RJ, Tang, C, Du, W, Kudchadker, RJ, Choi, S, Hoffman, K. Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized Prostate Cancer. Journal of Clinical Oncology 43(18):2044-2048, 2025. e-Pub 2025. PMID: 40367400.
- Hassanzadeh C, Kuban D, Pasyar S, Bassett R, Troncoso P, Schlembach P, McGuire S, Nguyen Q, Frank S, Mok H, Mohamad O, Park R, Shah S, Mayo L, Tang C, Du W, Kudchadker R, Choi S, Hoffman K. Hypofractionated, Dose-Escalated Radiation vs Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase 3, Prospective, Randomized Controlled Trial. Journal of Clinical Oncology. e-Pub 2025.
- Hassanzadeh, CJ, Mohamad, O, Bruno, TL, Wang, L, Kudchakar, R, Bathala, TK, Sanders, JW, Mok, H, McGuire, SE, Kuban, DA, Hoffman, K, Nguyen, Q, Park, RJ, Thames, HD, Corn, P, Chapin, BF, Choi, S, Tang, C, Frank, SJ. Early outcomes following local salvage treatment with MRI-assisted low-dose rate brachytherapy (MARS) for MRI-visible postsurgical bed recurrences and focal intraprostatic recurrences. Brachytherapy 24(2):231-237, 2025. e-Pub 2025. PMID: 39755443.
- Mohamad, O, Kouzi, ZE, Kouzy, R, Choi, S, Mok, H, Hoffman, K, Nguyen, Q, Hassanzadeh, CJ, Tang, C, Park, RJ, Shah, SJ, McGuire, SE, Mayo, LL, Kim, Y, Prajapati, S, Vijayan, S, Kudchadker, RJ, Bruno, TL, Frank, SJ. Safety and early outcomes of proton therapy and low-dose rate brachytherapy boost for patients with prostate cancer. Brachytherapy 24(2):1-9, 2025. e-Pub 2025. PMID: 40024668.
- Hassanzadeh C, Mohamad O, Bruno T, Wang L, Kudchakar R, Bathala T, Sanders J, Mok H, McGuire S, Kuban D, Hoffman K, Nguyen Q, Park R, Thames H, Corn P, Chapin B, Choi S, Tang C, Frank S. Early outcomes following salvage MARS brachytherapy for MRI-visible post-surgical bed recurrences and focal intraprostatic recurrences. Brachytherapy 24(2):231-237, 2025. e-Pub 2025. PMID: 39755443.
- Zhao, Y, Cozma, A, Ding, Y, Perles, LA, Reiazi, R, Chen, X, Kang, AM, Prajapati, S, Yu, H, Subashi, ED, Brock, K, Wang, J, Beddar, S, Lee, B, Mohammedsaid, M, Cooper, S, Westley, RL, Tree, A, Mohamad, O, Hassanzadeh, CJ, Mok, H, Choi, S, Tang, C, Yang, J. Upper Urinary Tract Stereotactic Body Radiotherapy Using a 1.5 Tesla Magnetic Resonance Imaging-Guided Linear Accelerator. Cancers 16(23), 2024. e-Pub 2024. PMID: 39682173.
- Carriere, P, Alhalabi, O, Gao, J, Mohamad, O, Campbell, M, Shah, AY, Goswami, S, Bree, KK, Lee, B, Navai, N, Mok, H, Mayo, LL, Guo, CC, Nguyen, Q, McGuire, SE, Park, R, Shah, SJ, Hoffman, K, Frank, SJ, Tang, C, Choi, S, Kamat, A, Hassanzadeh, CJ. Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer. Clinical and Translational Radiation Oncology 49, 2024. e-Pub 2024. PMID: 39403573.
- Sosa, A, Rooney, MK, Thames, HD, Sanders, JW, Swanson, DM, Choi, S, Nguyen, Q, Mok, H, Kuban, DA, Ron Zhu, X, Shah, SJ, Mayo, LL, Hoffman, K, Tang, C, McGuire, SE, Sahoo, N, Zhang, X, Lee, AK, Pugh, T, Mahmood, U, Davis, JW, Chapin, BF, Corn, P, Kudchadker, R, Ausat, N, Frank, SJ. Proton therapy toxicity outcomes for localized prostate cancer: Long-term results at a comprehensive cancer center. Clinical and Translational Radiation Oncology 48, 2024. e-Pub 2024. PMID: 39188999.
- Carriere P, Alhalabi O, Gao J, Mohamad O, Campbell M, Shah A, Goswami S, Bree K, Lee B, Navai N, Mok H, Mayo L, Guo C, Nguyen Q, McGuire S, Park R, Shah S, Hoffman K, Frank S, Tang C, Choi S, Kamat A, Hassanzadeh C. Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer. Clin Transl Radiat Oncol 28(49), 2024. PMID: 39403573.
- Sanders JW, Tang C, Kudchadker RJ, Venkatesan AM, Mok H, Hanania AN, Thames HD, Bruno TL, Starks C, Santiago E, Cunningham M, Frank SJ. Uncertainty in magnetic resonance imaging-based prostate postimplant dosimetry: Results of a 10-person human observer study, and comparisons with automatic postimplant dosimetry. Brachytherapy:822-832, 2023. e-Pub 2023. PMID: 37716820.
- Sosa AJ, Thames HD, Sanders JW, Choi SL, Nguyen QN, Mok H, Ron Zhu X, Shah S, Mayo LL, Hoffman KE, Tang C, Lee AK, Pugh TJ, Kudchadker R, Frank SJ. Proton Therapy for the Management of Localized Prostate Cancer: Long-Term Clinical Outcomes at a Comprehensive Cancer Center. Radiother Oncol 188:109854, 2023. e-Pub 2023. PMID: 37597805.
- Andring LM, Abu-Gheida I, Bathala T, Yoder AK, Manzar GS, Maldonado JA, Frank SJ, Choi S, Nguyen QN, Hoffman K, McGuire SE, Mok H, Aparicio A, Chapin BF, Tang C. Definitive local therapy for T4 prostate cancer associated with improved local control and survival. BJU Int 132(3):307-313, 2023. e-Pub 2023. PMID: 37057728.
- Tang C, Sanders J, Thames H, Swanson DM, Crook JM, Bruno T, Blanchard P, Ciezki J, Keyes M, Song D, Singh T, Merrick G, Stock R, Sullivan FJ, Mok H, Millar J, Frank SJ. Outcomes after PD-103 versus I-125 for Low Dose Rate Prostate Brachytherapy Monotherapy: An International, Multi-Institutional Study. Radiother Oncol 183:109599, 2023. e-Pub 2023. PMID: 36889593.
- Sanders JW, Mok H, Hanania AN, Venkatesan AM, Tang C, Bruno TL, Thames HD, Kudchadker RJ, Frank SJ. Computer-aided segmentation on MRI for prostate radiotherapy, Part I: Quantifying human interobserver variability of the prostate and organs at risk and its impact on radiation dosimetry. Radiother Oncol 169:124-131, 2022. e-Pub 2022. PMID: 34921895.
- Sanders JW, Mok H, Hanania AN, Venkatesan AM, Tang C, Bruno TL, Thames HD, Kudchadker RJ, Frank SJ. Computer-aided segmentation on MRI for prostate radiotherapy, part II: Comparing human and computer observer populations and the influence of annotator variability on algorithm variability. Radiother Oncol 169:132-139, 2022. e-Pub 2022. PMID: 34979213.
- Sanders JW, Kudchadker RJ, Tang C, Mok H, Venkatesan AM, Thames HD, Frank SJ. Prospective Evaluation of Prostate and Organs at Risk Segmentation Software for MRI-based Prostate Radiation Therapy. Radiol Artif Intell 4(2):e210151, 2022. e-Pub 2022. PMID: 35391775.
- Sada YH, Smaglo BG, Tran Cao HS, Mok H, Musher BL, Massarweh NN. National Trends in Multimodality Therapy for Locally Advanced Gastric Cancer. J Surg Res 237:41-49, 2019. e-Pub 2019. PMID: 30694790.
- Li, L, Mok, H, Jhaveri, P, Bonnen, M D, Sikora, A G, Eissa, N T, Komaki, R U, Ghebre, Y T. Anticancer therapy and lung injury: molecular mechanisms. Expert Rev Anticancer Ther, 2018. e-Pub 2018. PMID: 29996062.
- Pham, N, Asper, J, Bonnen, M, Mok, H, Wagner, T, Ludwig, M, Carpenter, L, Jhaveri, P. Pre-treatment peer-review: enhancing value through increased efficiency and effectiveness of radiation oncology peer review. Journal of Radiation Oncology 7:97-102, 2018. e-Pub 2018.
- Chen AC, Bonnen MD, Mok H. Onsite versus offsite radiation treatment of malignant spinal cord compression: lessons from a safety net health system. Br J Radiol 90(1072):20160922, 2017. e-Pub 2017. PMID: 28181815.
- Wald O, Smaglo B, Mok H, Groth SS. Future directions in esophageal cancer therapy. Ann Cardiothorac Surg 6(2):159-166, 2017. e-Pub 2017. PMID: 28447005.
- Hoffmann MS, Leslie LA, Jacobs RW, Millas S, Surabhi V, Mok H, Jhaveri P, Kott MM, Jackson L, Rieber A, Bhadkamkar NA. Reducing the Time From Diagnosis to Treatment of Patients With Stage II/III Rectal Cancer at a Large Public Hospital. J Oncol Pract 12(2):e257-62, 2016. e-Pub 2016. PMID: 26869658.
- Briere TM, Crane CH, Beddar S, Bhosale P, Mok H, Delclos ME, Krishnan S, Das P. Reproducibility and genital sparing with a vaginal dilator used for female anal cancer patients. Radiother Oncol 104(2):161-6, 2012. e-Pub 2012. PMID: 22841019.
- Chakravarty T, Crane CH, Ajani JA, Mansfield PF, Briere TM, Beddar AS, Mok H, Reed VK, Krishnan S, Delclos ME, Das P. Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma. Int J Radiat Oncol Biol Phys 83(2):581-6, 2012. e-Pub 2012. PMID: 22137021.
- Mok H, Briere TM, Martel MK, Beddar S, Delclos ME, Krishnan S, Crane CH, Das P. Comparative analysis of volumetric modulated arc therapy versus intensity modulated radiation therapy for radiotherapy of anal carcinoma. Pract Radiat Oncol 1(3):163-72, 2011. e-Pub 2011. PMID: 24673946.
- Mok H, Crane CH, Palmer MB, Briere TM, Beddar S, Delclos ME, Krishnan S, Das P. Intensity modulated radiation therapy (IMRT): differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma. Radiat Oncol 6:63, 2011. e-Pub 2011. PMID: 21651775.
- Debeb BG, Xu W, Mok H, Li L, Robertson F, Ueno NT, Reuben J, Lucci A, Cristofanilli M, Woodward WA. Differential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions. Int J Radiat Oncol Biol Phys 76(3):889-95, 2010. e-Pub 2010. PMID: 20159363.
- Mok H, Mlodnicka AE, Hentze MW, Muckenthaler M, Schumacher A. The molecular circuitry regulating the switch between iron deficiency and overload in mice. J Biol Chem 281(12):7946-51, 2006. e-Pub 2006. PMID: 16418170.
- Mok H, Mendoza M, Prchal JT, Balogh P, Schumacher A. Dysregulation of ferroportin 1 interferes with spleen organogenesis in polycythaemia mice. Development 131(19):4871-81, 2004. e-Pub 2004. PMID: 15342464.
- Mok H, Jelinek J, Pai S, Cattanach BM, Prchal JT, Youssoufian H, Schumacher A. Disruption of ferroportin 1 regulation causes dynamic alterations in iron homeostasis and erythropoiesis in polycythaemia mice. Development 131(8):1859-68, 2004. e-Pub 2004. PMID: 15084469.
- Kruyt FA, Abou-Zahr F, Mok H, Youssoufian H. Resistance to mitomycin C requires direct interaction between the Fanconi anemia proteins FANCA and FANCG in the nucleus through an arginine-rich domain. J Biol Chem 274(48):34212-8, 1999. e-Pub 1999. PMID: 10567393.
Abstracts
- Sada, Y H, Smaglo, B G, Cao, H T, Akce, M, Mok, H, Musher, B L, Massarweh, N N. Trends in multimodality therapy for gastric cancer post-MAGIC:35, 2017. e-Pub 2017.
- Smaglo, B G, Sada, Y, Cao, H T, Akce, M, Mok, H, Musher, B L, Massarweh, N N. Pathologic nodal response in gastric cancer: Do all patients need adjuvant therapy?:35, 2017. e-Pub 2017.
- Chen, A C, Mok, H. Metastatic Spinal Cord Compression: Comparing Two Treatment Eras, 2015. e-Pub 2015.
Patient Reviews
CV information above last modified August 25, 2026